Sponsored

Northwell, The START Center for Cancer Research to Form Strategic Partnership

July 24th 2024

New START early-phase clinical trial site brings advanced cancer research to Northwell’s Cancer Institute, increases patient access

LYNPARZA® (olaparib): 10 Years Dedicated to Transforming Certain Types of Cancer

July 16th 2024

Temple University Hospital and Fox Chase Cancer Center Researchers Characterize HER2 Mutations in Patients With Lung Adenocarcinoma

July 13th 2024

Ochsner Health Wins Innovator Award Funds for Connected MOM

July 12th 2024

The HHS competition evaluated the effectiveness of Ochsner Connected MOM in increasing blood pressure monitoring during pregnancy and the postpartum period.

Fox Chase Cancer Center Appoints Dr. Jeffrey M. Farma Chair of Surgery

July 10th 2024

Jeffrey M. Farma, MD, FACS, has been appointed Chair of Surgery at Fox Chase Cancer Center.

New Study from Roswell Park Pinpoints Cells That May Drive Treatment Resistance in Prostate Cancer

July 8th 2024

Using multiomics, the team identifies novel therapeutic targets in castration-resistant prostate cancer.

Hope With the Help of Dual I-O

July 8th 2024

Anti-Inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence For a Subset of Patients

July 1st 2024

A study found stage 3 colon cancer patients with PIK3CA mutations taking celecoxib post-surgery had longer survival and disease-free intervals.

MDS and AML, Two Distinct Disease Entities on a Continuum

June 28th 2024

Myelodysplastic neoplasms (MDS; also known as Myelodysplastic Syndromes), and acute myeloid leukemia (AML) are two related but distinct disease entities requiring differential treatment approaches. Watch this video to find out more on the biological, morphological, and clinical differences between the two diseases, and why patient-centric, tailored treatment approaches are important to manage patients with either MDS or AML.

The Role of Immunotherapy in the Treatment of First-Line ES-SCLC

June 26th 2024

Bispecific antibodies in multiple myeloma: revolutionizing blood cancer immunotherapy

June 21st 2024

Real-World Data on an RAI-Refractory DTC Treatment Option

June 14th 2024

Researcher and clinician, Dr. Francis Worden, reflects on advancements in the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) and the value of real-world data to provide insights from clinical practice

Long-term Data in Patients with Metastatic Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Alterations

June 7th 2024

Exploring Tumor Treating Fields Therapy

May 2nd 2024

THIS ARTICLE IS SPONSORED BY NOVOCURE®. This article includes expert insights from Moshe Giladi, PhD; and Narasimha Kumar Karanam, PhD, BCMAS. Giladi, Novocure’s Chief Science Officer, oversees Novocure’s preclinical research organization and manages external research partnerships and Novocure’s biostatistics and data management teams. Karanam is Novocure’s Medical Science Liaison and has researched the mechanisms of action underlying tumor treating fields therapy.

PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse

April 25th 2024

Thomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.

The Impact of CAR T Cell Therapy on Managing R/R LBCL

April 17th 2024

CAR T cell therapies have shown remarkable clinical success in difficult-to-treat blood cancers. Read one oncologist’s perspective on what current CAR T therapies may offer patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including at earlier points in their disease journey.

Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell Lymphoma

January 24th 2024

Many people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.

It’s Time to Address Patient Needs: The Changing Landscape of Colorectal Cancer Treatment

January 8th 2024

Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial

December 5th 2023

SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.

Biomarker Testing and Targeted Therapy in NSCLC: Review and Update (Podcast)

November 27th 2023

Expert Derek Lyle, MD, provides an in-depth overview of biomarker testing and targeted therapy in the current landscape of non–small cell lung cancer management.